Taiwan · Delayed Price · Currency is TWD AmCad BioMed Statistics
Total Valuation
AmCad BioMed has a market cap or net worth of TWD 668.16 million. The enterprise value is 410.09 million.
| Market Cap | 668.16M |
| Enterprise Value | 410.09M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 5.17% in one year.
| Current Share Class | 63.33M |
| Shares Outstanding | 63.33M |
| Shares Change (YoY) | +5.17% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.64% |
| Owned by Institutions (%) | 0.95% |
| Float | 31.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.24 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.50 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.23, with a Debt / Equity ratio of 0.03.
| Current Ratio | 23.23 |
| Quick Ratio | 21.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -751.88 |
Financial Efficiency
Return on equity (ROE) is -11.22% and return on invested capital (ROIC) is -8.55%.
| Return on Equity (ROE) | -11.22% |
| Return on Assets (ROA) | -8.37% |
| Return on Invested Capital (ROIC) | -8.55% |
| Return on Capital Employed (ROCE) | -14.42% |
| Weighted Average Cost of Capital (WACC) | 5.71% |
| Revenue Per Employee | 883,647 |
| Profits Per Employee | -1.58M |
| Employee Count | 34 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.67 |
Taxes
| Income Tax | -15,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.87% in the last 52 weeks. The beta is 0.29, so AmCad BioMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.29 |
| 52-Week Price Change | -35.87% |
| 50-Day Moving Average | 11.45 |
| 200-Day Moving Average | 13.96 |
| Relative Strength Index (RSI) | 37.14 |
| Average Volume (20 Days) | 74,387 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AmCad BioMed had revenue of TWD 30.04 million and -53.66 million in losses. Loss per share was -0.85.
| Revenue | 30.04M |
| Gross Profit | 10.74M |
| Operating Income | -84.96M |
| Pretax Income | -68.36M |
| Net Income | -53.66M |
| EBITDA | -74.27M |
| EBIT | -84.96M |
| Loss Per Share | -0.85 |
Balance Sheet
The company has 349.19 million in cash and 14.50 million in debt, with a net cash position of 334.69 million or 5.28 per share.
| Cash & Cash Equivalents | 349.19M |
| Total Debt | 14.50M |
| Net Cash | 334.69M |
| Net Cash Per Share | 5.28 |
| Equity (Book Value) | 579.14M |
| Book Value Per Share | 7.93 |
| Working Capital | 375.04M |
Cash Flow
In the last 12 months, operating cash flow was -46.91 million and capital expenditures -201,000, giving a free cash flow of -47.11 million.
| Operating Cash Flow | -46.91M |
| Capital Expenditures | -201,000 |
| Depreciation & Amortization | 10.69M |
| Net Borrowing | -4.91M |
| Free Cash Flow | -47.11M |
| FCF Per Share | -0.74 |
Margins
Gross margin is 35.73%, with operating and profit margins of -282.80% and -178.59%.
| Gross Margin | 35.73% |
| Operating Margin | -282.80% |
| Pretax Margin | -227.55% |
| Profit Margin | -178.59% |
| EBITDA Margin | -247.20% |
| EBIT Margin | -282.80% |
| FCF Margin | n/a |
Dividends & Yields
AmCad BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.17% |
| Shareholder Yield | -5.17% |
| Earnings Yield | -8.03% |
| FCF Yield | -7.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AmCad BioMed has an Altman Z-Score of 20.73 and a Piotroski F-Score of 1.
| Altman Z-Score | 20.73 |
| Piotroski F-Score | 1 |